For the quarter ending 2025-09-30, PHAT made $49,504,000 in revenue. -$29,973,000 in net income. Net profit margin of -60.55%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Product revenue, net | 49,504,000 | 39,503,000 | 28,519,000 | 12,966,666.667 |
| Cost of revenue | 6,190,000 | 5,038,000 | 3,724,000 | 1,872,333.333 |
| Gross profit | 43,314,000 | 34,465,000 | 24,795,000 | 11,094,333.333 |
| Research and development | 7,027,000 | 9,076,000 | 9,184,000 | 8,463,000 |
| Selling, general and administrative | 51,558,000 | 85,313,000 | 94,474,000 | 71,521,666.667 |
| Total operating expenses | 58,585,000 | 94,389,000 | 103,658,000 | 79,984,666.667 |
| Loss from operations | -15,271,000 | -59,924,000 | -78,863,000 | -68,890,333.333 |
| Interest income | 1,413,000 | 1,787,000 | 2,640,000 | 3,815,666.667 |
| Interest expense | 16,108,000 | 17,518,000 | 18,071,000 | 17,841,666.667 |
| Other expense, net | -7,000 | -155,000 | -22,000 | 0 |
| Total other expense | -14,702,000 | -15,886,000 | -15,453,000 | -14,026,000 |
| Net loss and comprehensive loss | -29,973,000 | -75,810,000 | -94,316,000 | -82,916,333.333 |
| Net loss per share, basic | -0.41 | -1.05 | -1.31 | -1.323 |
| Net loss per share, diluted | -0.41 | -1.05 | -1.31 | -1.323 |
| Weighted-average shares of common stock outstanding, basic | 73,396,435 | 72,466,203 | 71,969,411 | -483,879 |
| Weighted-average shares of common stock outstanding, diluted | 73,396,435 | 72,466,203 | 71,969,411 | -483,879 |
Phathom Pharmaceuticals, Inc. (PHAT)
Phathom Pharmaceuticals, Inc. (PHAT)